GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (STU:DOA) » Definitions » Cyclically Adjusted PB Ratio

Soligenix (STU:DOA) Cyclically Adjusted PB Ratio : (As of May. 23, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Soligenix Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Soligenix Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Soligenix's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soligenix Cyclically Adjusted PB Ratio Chart

Soligenix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 1.18 1.31 15.86 19.79

Soligenix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 19.79 0.56

Competitive Comparison of Soligenix's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Soligenix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soligenix's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Soligenix's Cyclically Adjusted PB Ratio falls into.



Soligenix Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Soligenix's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Soligenix's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.068/131.7762*131.7762
=0.068

Current CPI (Mar. 2024) = 131.7762.

Soligenix Quarterly Data

Book Value per Share CPI Adj_Book
201406 -25.746 100.560 -33.738
201409 -22.571 100.428 -29.617
201412 -0.783 99.070 -1.041
201503 -9.986 99.621 -13.209
201506 -17.835 100.684 -23.343
201509 -2.300 100.392 -3.019
201512 -0.082 99.792 -0.108
201603 -4.509 100.470 -5.914
201606 0.137 101.688 0.178
201609 7.723 101.861 9.991
201612 19.228 101.863 24.875
201703 14.905 102.862 19.095
201706 8.510 103.349 10.851
201709 6.683 104.136 8.457
201712 9.175 104.011 11.624
201803 5.665 105.290 7.090
201806 3.848 106.317 4.769
201809 6.738 106.507 8.337
201812 4.682 105.998 5.821
201903 3.855 107.251 4.737
201906 2.576 108.070 3.141
201909 1.783 108.329 2.169
201912 0.904 108.420 1.099
202003 1.851 108.902 2.240
202006 2.810 108.767 3.404
202009 3.160 109.815 3.792
202012 1.506 109.897 1.806
202103 5.453 111.754 6.430
202106 4.845 114.631 5.570
202109 4.503 115.734 5.127
202112 3.320 117.630 3.719
202203 2.088 121.301 2.268
202206 1.386 125.017 1.461
202209 0.363 125.227 0.382
202212 -0.802 125.222 -0.844
202303 -1.080 127.348 -1.118
202306 0.544 128.729 0.557
202309 0.381 129.860 0.387
202312 0.223 129.419 0.227
202403 0.068 131.776 0.068

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Soligenix  (STU:DOA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Soligenix Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Soligenix's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Soligenix (STU:DOA) Business Description

Industry
Traded in Other Exchanges
Address
29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Soligenix (STU:DOA) Headlines

No Headlines